AbbVie has agreed to pay $700 million upfront to IGI Therapeutics for licensing rights to ISB-2001, a trispecific antibody candidate targeting multiple myeloma. The antibody engages three targets—CD3 on T cells and BCMA and CD38 on tumor cells—offering a multi-faceted mechanism to kill cancer cells. Early Phase 1 data reflect encouraging response rates and a manageable safety profile. The deal includes potential milestone payments and royalties, reflecting AbbVie’s strategy to bolster its oncology pipeline with innovative multi-specific therapeutics.